Just one relapse episode significantly increased all-cause mortality in people with relatively stable schizophrenia, a ...

Patients with GPA completely weaned off glucocorticoids were four times as likely to flare compared with those kept on a low ...

Researchers have developed a mindfulness therapy tailored specifically to appeal to teenagers to help them cope with increasing levels of depression and mental health problems.

In a statistically significant showing, treatment with Caplyta led to a longer time to relapse than placebo in schizophrenia patients, Intra-Cellular said Tuesday, citing top-line results from a ...

Check if you have access via personal or institutional login The first workbook written for individuals progressing through the Recovery Resilience Program, a person-centered, strength and ...

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

The FDA-approved schizophrenia and bipolar disorder therapy met the primary and secondary endpoint in a Phase III “withdrawal ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

The findings, derived from Study 304, a randomized withdrawal trial, revealed that lumateperone significantly extended the time to relapse for patients compared to a placebo. Schizophrenia ...

VIENNA — A diet high in ultraprocessed foods (UPFs) increases the risk for clinical relapse in patients with Crohn’s disease (CD) who are in remission, results of a new study suggested.

Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with ...